The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter international phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.
Keith Christopher Bible
No relevant relationships to disclose
Vera J. Suman
No relevant relationships to disclose
Julian R. Molina
No relevant relationships to disclose
Robert C. Smallridge
No relevant relationships to disclose
William James Maples
No relevant relationships to disclose
Michael E. Menefee
No relevant relationships to disclose
Joseph Rubin
No relevant relationships to disclose
Nina J. Karlin
No relevant relationships to disclose
Kostandinos Sideras
No relevant relationships to disclose
John C. Morris
No relevant relationships to disclose
Bryan McIver
No relevant relationships to disclose
Ian D. Hay
No relevant relationships to disclose
Vahab Fatourechi
No relevant relationships to disclose
Jill K. Burton
No relevant relationships to disclose
Anne M. Traynor
No relevant relationships to disclose
Patrick J. Flynn
No relevant relationships to disclose
Boon C. Goh
No relevant relationships to disclose
Crescent R Isham
No relevant relationships to disclose
Pamela Jo Harris
No relevant relationships to disclose
Charles Erlichman
No relevant relationships to disclose